Baidu
map

Allergy:青少年到成年人群体中,过敏性鼻炎预测因子分析

2018-10-27 AlexYang MedSci原创

虽然儿童的遗传性过敏疾病已经了解很短哦,但是从儿童到成年人中,遗传过敏性疾病的持久性相关知识却非常有限。最近,有研究人员在一个非选择性青少年群体中研究了遗传过敏性疾病和I型敏感症的临床特点,并跟踪调查到成年人阶段。研究人员发现,遗传过敏性疾病的流行度高,并且从青少年(31%)到成年人(57%)过程中具有显著的增加,尤其是过敏性鼻炎,发生率增加的幅度为17.5/1000人/年。成年过敏性鼻炎的儿童时

虽然儿童的遗传性过敏疾病已经了解很多,但是从儿童到成年人中,遗传过敏性疾病的持久性相关知识却非常有限。最近,有研究人员在一个非选择性青少年群体中研究了遗传过敏性疾病和I型敏感症的临床特点,并跟踪调查到成年人阶段。

研究人员发现,遗传过敏性疾病的流行度高,并且从青少年(31%)到成年人(57%)过程中具有显著的增加,尤其是过敏性鼻炎,发生率增加的幅度为17.5/1000人/年。成年过敏性鼻炎的儿童时期预测因子为遗传性皮肤炎,哮喘和无症状花粉和屋尘螨过敏。在那些具有无症状的青少年中,53%-78%比例在成年人时期发展为过敏性鼻炎。进一步的是,I型敏感症从青少年到成年人的显著增加大多是由于对花粉的敏感引起。另外,I型敏感症主要在过敏性鼻炎的患者中发现。由于对桦树花粉过敏的个体数较多,具有口服过敏症状的成年人也较多。

最后,研究人员指出,遗传性过敏性疾病的持久性是常见的,并且由于成年人群体敏感比例高,因此过敏性鼻炎的流行度也高。许多具有无症状敏感的青少年在成年人时期发展为过敏性鼻炎。因此,研究人员强调,应该在儿童时期对遗传性过敏疾病和敏感进行预防

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2047035, encodeId=ffd3204e03541, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Mon Jan 21 05:31:00 CST 2019, time=2019-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1717002, encodeId=ddfe1e1700221, content=<a href='/topic/show?id=f8a98002eb1' target=_blank style='color:#2F92EE;'>#群体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80027, encryptionId=f8a98002eb1, topicName=群体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c0832353243, createdName=xjy13, createdTime=Sun May 12 09:31:00 CST 2019, time=2019-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1774865, encodeId=df691e748658c, content=<a href='/topic/show?id=946053989b3' target=_blank style='color:#2F92EE;'>#成年人群#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53989, encryptionId=946053989b3, topicName=成年人群)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f4738693938, createdName=zhyy101, createdTime=Thu May 09 13:31:00 CST 2019, time=2019-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1310702, encodeId=2d341310e02b5, content=<a href='/topic/show?id=25dc1002255e' target=_blank style='color:#2F92EE;'>#预测因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100225, encryptionId=25dc1002255e, topicName=预测因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6105386, createdName=宋威, createdTime=Mon Oct 29 05:31:00 CST 2018, time=2018-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329165, encodeId=34fb1329165f7, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Mon Oct 29 05:31:00 CST 2018, time=2018-10-29, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2047035, encodeId=ffd3204e03541, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Mon Jan 21 05:31:00 CST 2019, time=2019-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1717002, encodeId=ddfe1e1700221, content=<a href='/topic/show?id=f8a98002eb1' target=_blank style='color:#2F92EE;'>#群体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80027, encryptionId=f8a98002eb1, topicName=群体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c0832353243, createdName=xjy13, createdTime=Sun May 12 09:31:00 CST 2019, time=2019-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1774865, encodeId=df691e748658c, content=<a href='/topic/show?id=946053989b3' target=_blank style='color:#2F92EE;'>#成年人群#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53989, encryptionId=946053989b3, topicName=成年人群)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f4738693938, createdName=zhyy101, createdTime=Thu May 09 13:31:00 CST 2019, time=2019-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1310702, encodeId=2d341310e02b5, content=<a href='/topic/show?id=25dc1002255e' target=_blank style='color:#2F92EE;'>#预测因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100225, encryptionId=25dc1002255e, topicName=预测因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6105386, createdName=宋威, createdTime=Mon Oct 29 05:31:00 CST 2018, time=2018-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329165, encodeId=34fb1329165f7, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Mon Oct 29 05:31:00 CST 2018, time=2018-10-29, status=1, ipAttribution=)]
    2019-05-12 xjy13
  3. [GetPortalCommentsPageByObjectIdResponse(id=2047035, encodeId=ffd3204e03541, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Mon Jan 21 05:31:00 CST 2019, time=2019-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1717002, encodeId=ddfe1e1700221, content=<a href='/topic/show?id=f8a98002eb1' target=_blank style='color:#2F92EE;'>#群体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80027, encryptionId=f8a98002eb1, topicName=群体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c0832353243, createdName=xjy13, createdTime=Sun May 12 09:31:00 CST 2019, time=2019-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1774865, encodeId=df691e748658c, content=<a href='/topic/show?id=946053989b3' target=_blank style='color:#2F92EE;'>#成年人群#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53989, encryptionId=946053989b3, topicName=成年人群)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f4738693938, createdName=zhyy101, createdTime=Thu May 09 13:31:00 CST 2019, time=2019-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1310702, encodeId=2d341310e02b5, content=<a href='/topic/show?id=25dc1002255e' target=_blank style='color:#2F92EE;'>#预测因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100225, encryptionId=25dc1002255e, topicName=预测因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6105386, createdName=宋威, createdTime=Mon Oct 29 05:31:00 CST 2018, time=2018-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329165, encodeId=34fb1329165f7, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Mon Oct 29 05:31:00 CST 2018, time=2018-10-29, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2047035, encodeId=ffd3204e03541, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Mon Jan 21 05:31:00 CST 2019, time=2019-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1717002, encodeId=ddfe1e1700221, content=<a href='/topic/show?id=f8a98002eb1' target=_blank style='color:#2F92EE;'>#群体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80027, encryptionId=f8a98002eb1, topicName=群体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c0832353243, createdName=xjy13, createdTime=Sun May 12 09:31:00 CST 2019, time=2019-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1774865, encodeId=df691e748658c, content=<a href='/topic/show?id=946053989b3' target=_blank style='color:#2F92EE;'>#成年人群#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53989, encryptionId=946053989b3, topicName=成年人群)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f4738693938, createdName=zhyy101, createdTime=Thu May 09 13:31:00 CST 2019, time=2019-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1310702, encodeId=2d341310e02b5, content=<a href='/topic/show?id=25dc1002255e' target=_blank style='color:#2F92EE;'>#预测因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100225, encryptionId=25dc1002255e, topicName=预测因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6105386, createdName=宋威, createdTime=Mon Oct 29 05:31:00 CST 2018, time=2018-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329165, encodeId=34fb1329165f7, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Mon Oct 29 05:31:00 CST 2018, time=2018-10-29, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2047035, encodeId=ffd3204e03541, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Mon Jan 21 05:31:00 CST 2019, time=2019-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1717002, encodeId=ddfe1e1700221, content=<a href='/topic/show?id=f8a98002eb1' target=_blank style='color:#2F92EE;'>#群体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80027, encryptionId=f8a98002eb1, topicName=群体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c0832353243, createdName=xjy13, createdTime=Sun May 12 09:31:00 CST 2019, time=2019-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1774865, encodeId=df691e748658c, content=<a href='/topic/show?id=946053989b3' target=_blank style='color:#2F92EE;'>#成年人群#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53989, encryptionId=946053989b3, topicName=成年人群)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f4738693938, createdName=zhyy101, createdTime=Thu May 09 13:31:00 CST 2019, time=2019-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1310702, encodeId=2d341310e02b5, content=<a href='/topic/show?id=25dc1002255e' target=_blank style='color:#2F92EE;'>#预测因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100225, encryptionId=25dc1002255e, topicName=预测因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6105386, createdName=宋威, createdTime=Mon Oct 29 05:31:00 CST 2018, time=2018-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329165, encodeId=34fb1329165f7, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Mon Oct 29 05:31:00 CST 2018, time=2018-10-29, status=1, ipAttribution=)]
    2018-10-29 膀胱癌

相关资讯

儿童过敏性鼻炎,应该如何用药?

随着生活环境的变化,过敏性鼻炎(又称变应性鼻炎)已成为儿童的常见病和多发病。据统计,我国儿童过敏性鼻炎的患病率已高达7.83%~29.42%。过敏性鼻炎难以根治,合理用药非常重要。一、过敏鼻炎与普通感冒的简单鉴别1、病因不同:普通感冒是由病毒(其中鼻病毒约占30%~50%)引起的感染性疾病;而过敏性鼻炎是机体接触过敏原后,由IgE介导的非感染性炎性疾病。2、症状不同:普通感冒常有伴咽痛、发热和全身

J Coll Physicians Surg Pak:过敏性鼻炎患者中,常见过敏原的皮刺试验反应研究

最近,有研究人员鉴定了在过敏性鼻炎患者中,引起过敏症状的常见过敏原。研究是一个代表性的研究。包括了那些临床诊断为过敏性鼻炎的患者。研究人员对这些患者进行了皮刺试验(SPT),使用了12中常见的气源性过敏原。试验中包括了阳性对照和阴性对照,并记录了处理15分钟后的结果,并将水泡直径大于3毫米作为阳性反应。研究发现,在130名患者中,78(60%)名为男性,52(40%)名为女性。对任何一种过敏原敏感

Allergy Asthma Clin Immunol:5种草花粉提取混合物舌下免疫治疗的观察性群体研究

过敏性鼻炎影响着西方欧洲人口群体的四分之一之多。预防过敏源免疫疗法在减少急性症状发作(花粉过敏)中是有效的。到目前为止,一种5种草花粉提取混合物舌下免疫治疗(5GPE-SLIT)被用来治疗花粉过敏的过敏性鼻炎。最近,有研究人员描述了真实世界中5GPE-SLIT的治疗情况。研究包括了280名成年人和203名儿童。处方信息包括了82.5%的成年人和86.7%的儿童。研究人员对所有的患者进行了皮刺测试。

Immun Inflamm Dis:永久过敏性鼻炎患者中,MP-AzeFlu治疗效果分析

大多数过敏性鼻炎(AR)患者患有中度到重度以及永久性症状。MP-AzeFlu组合鼻内盐酸氮卓斯汀(AZE)和氟替卡松丙酸酯(FP)可以作为一种新的治疗方法来治疗AR。最近,有研究人员在一个前瞻性的和非介入性研究中探索和评估了MP-AzeFlu在减轻AR症状严重度中的效果。研究人员发现,那些使用MP-AzeFlu的患者的VAS评分从开始的73.4mm(SD.20.3)快速降低到了第28天的31.5m

Wiad Lek:过敏性和非过敏性鼻炎冷冻手术研究

过敏和非过敏性鼻炎的药物治疗并非总是有效的。最近,有研究人员在过敏和非过敏血管收缩性鼻炎患者中,评估了冷冻手术的治疗效果。研究包括了60名患者,包括28名女性和32名男性,年龄在17-76岁之间,平均年龄为39岁。所有的参与者被分成2组,组1:18名患有慢性过敏性鼻炎的患者;组2:42名患有慢性非过敏性血管舒缩性鼻炎患者。研究的方法包括鼻内窥镜、耳鼻喉检查和鼻压力计检查,分别在手术的前后3个月内进

Int Forum Allergy Rhinol:儿童中过敏性鼻炎和夜尿症相关风险研究

尽管有争论,过敏和夜尿症(NE)之间的相关性在近一个世纪里均有报道。过敏性鼻炎(AR)相关的睡眠障碍呼吸经常导致睡眠的微觉醒,从而减少了睡眠的质量,改变了睡眠模式和行为。NE是儿童中一种常见的睡眠障碍。因此,有研究人员调查了AR儿童的NE发生和风险情况。研究是一个基于群体的研究,包括了327928名患有AR的儿童和327601名不患有AR的对照儿童。时间为2012年,地点为中国台湾到2012年。研

Baidu
map
Baidu
map
Baidu
map